AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The deal adds Cerevel assets to AbbVie's neuroscience pipeline and sets up follow-on readouts to watch.

IntelligenceRegulatory Impact▾

U.S. Federal Trade Commission decisions frame this story. Regulatory relevance is high for immunology, with Emraclidine and Skyrizi most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• AbbVie completed the Cerevel Therapeutics acquisition on August 1, 2024, for $8.7 billion.
• The deal was structured at $45.00 per share in cash and cleared after FTC review.
• Emraclidine remains the key asset to watch, but its phase 2 history creates both optionality and execution risk.

IntelligenceCompetitive Intelligence▾

AbbVie and Cerevel Therapeutics are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

AbbVie closes the Cerevel acquisition

AbbVie finalized its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The transaction acquired all outstanding Cerevel shares for $45.00 per share in cash. With regulatory clearance complete, the story now shifts from deal announcement to asset integration and catalyst tracking for BD teams and investors evaluating the strategic fit and clinical viability of Cerevel's pipeline within AbbVie's broader neuroscience franchise.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for immunology. Expect implications for pricing, access, and launch sequencing.

Emraclidine defines the near-term asset story

Emraclidine is the flagship Cerevel asset now under AbbVie's ownership, and its clinical trajectory will largely determine the deal's success. The compound carries notable execution risk: emraclidine was a key asset in Cerevel's pipeline prior to phase 2 clinical trial failures. Prior phase 2 studies in schizophrenia—NCT05227703 and NCT05227690—have been completed, providing a historical record of the compound's tolerability and efficacy profile that AbbVie must now navigate.

AbbVie has initiated a series of new trials to characterize emraclidine further. NCT07587008 is a phase 1 study assessing adverse events and pharmacokinetics in healthy adult volunteers, currently in not-yet-recruiting status. NCT07219030, a phase 1 trial in healthy elderly participants, is actively recruiting. Most critically, NCT07145918 is a phase 2 study assessing adverse events, disease activity, and pharmacokinetics in adults with schizophrenia, also recruiting. These trials will be the primary catalysts for investors tracking whether AbbVie can rehabilitate the emraclidine program or whether the prior phase 2 setbacks remain insurmountable.

IntelligenceStrategic Takeaways▾

AbbVie completed the Cerevel Therapeutics acquisition on August 1, 2024, for $8.7 billion. The deal was structured at $45.00 per share in cash and cleared after FTC review. Emraclidine remains the key asset to watch, but its phase 2 history creates both optionality and execution risk.

AbbVie's broader portfolio offsets neuroscience risk

While emraclidine carries clinical risk, AbbVie's core business remains robust. Immunology generated $30.41 billion in revenue in 2025, representing a 14.0% increase. Within that segment, Skyrizi revenues increased nearly 50% to $17.56 billion in 2025. Skyrizi is indicated for the treatment of moderate-to-severe plaque psoriasis and moderately to severely active Crohn's disease in adults, anchoring AbbVie's immunology franchise.

AbbVie's neuroscience segment grew by 19.6% in 2025, demonstrating that the company's existing psychiatry and neurology portfolio—including Vraylar and Botox Therapeutic—continues to deliver growth independent of Cerevel. This means the Cerevel acquisition functions as a pipeline-restocking move rather than a portfolio rescue. The deal adds optionality in psychiatric and neurological indications, but AbbVie is not dependent on emraclidine's success to sustain its neuroscience momentum.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source.

What to watch next

BD teams and investors should monitor AbbVie's disclosure of enrollment progress and safety data from the active emraclidine trials. Key catalysts include completion of NCT07219030 (phase 1 in healthy elderly participants) and interim or topline readouts from NCT07145918 (phase 2 in schizophrenia). Any disclosure that clarifies whether emraclidine can overcome its prior phase 2 setbacks will be material to assessing whether Cerevel assets can support AbbVie's neuroscience growth narrative or whether the deal represents a high-risk, optionality-only acquisition.

Frequently Asked Questions